SOLIGENIX, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
SOLIGENIX, INC. (SNGX) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $416.10 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-07
- SOLIGENIX, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $93.80K.
- SOLIGENIX, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $322.31K, a 53.38% decline year-over-year.
- SOLIGENIX, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$47.15K, a 105.25% decline year-over-year.
- SOLIGENIX, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$375.22K.
- SOLIGENIX, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was -$16.50K.
- SOLIGENIX, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was -$492.61K.
- SOLIGENIX, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was -$2.69M, a 776.94% decline from fiscal 2022.
- SOLIGENIX, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was $396.65K, a 64.81% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $93.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $416.10K 10-Q · filed 2026-08-07 | $368.95K derived: sum of 3 quarters · filed 2026-08-07 | -$6.27K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $322.31K 10-Q · filed 2026-05-08 | $275.15K derived: sum of 2 quarters · filed 2026-05-08 | -$100.06K derived: sum of 3 quarters · filed 2026-05-08 | -$385.48K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | -$47.15K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$422.37K derived: sum of 2 quarters · filed 2026-03-31 | -$707.79K derived: sum of 3 quarters · filed 2026-08-07 | -$16.50K 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$375.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$660.64K derived: sum of 2 quarters · filed 2026-08-07 | $30.65K 10-Q · filed 2025-11-07 | $929.47K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | -$285.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $405.87K 10-Q · filed 2026-08-07 | $1.30M derived: sum of 3 quarters · filed 2026-08-07 | $144.34K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $691.29K 10-Q · filed 2026-05-08 | $976.78K 10-Q · filed 2025-05-09 | $1.59M derived: sum of 2 quarters · filed 2026-05-08 | $429.77K derived: sum of 3 quarters · filed 2026-05-08 | -$193.25K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $898.82K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$261.52K derived: sum of 2 quarters · filed 2026-03-31 | -$884.54K derived: sum of 3 quarters · filed 2026-03-31 | -$492.61K 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.78M derived: sum of 2 quarters · filed 2025-11-07 | -$1.39M 10-Q · filed 2025-11-07 | -$1.69M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | -$623.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$231.09K 10-Q · filed 2025-08-14 | -$533.45K derived: sum of 3 quarters · filed 2025-08-14 | -$1.31M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $391.93K 10-Q · filed 2025-05-09 | $89.56K derived: sum of 2 quarters · filed 2025-05-09 | -$688.73K derived: sum of 3 quarters · filed 2025-05-09 | -$1.32M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | -$302.37K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$1.08M derived: sum of 2 quarters · filed 2025-03-21 | -$1.71M derived: sum of 3 quarters · filed 2025-03-21 | -$2.69M 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$778.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$1.41M derived: sum of 2 quarters · filed 2024-11-08 | -$2.38M 10-Q · filed 2024-11-08 | -$2.67M derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | -$633.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$1.60M 10-Q · filed 2024-08-09 | -$1.89M derived: sum of 3 quarters · filed 2024-08-09 | -$2.00M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | -$970.76K 10-Q · filed 2024-05-10 | -$1.25M derived: sum of 2 quarters · filed 2024-05-10 | -$1.37M derived: sum of 3 quarters · filed 2024-05-10 | -$1.80M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | -$282.62K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$396.67K derived: sum of 2 quarters · filed 2024-03-15 | -$831.73K derived: sum of 3 quarters · filed 2024-03-15 | $396.65K 10-K · filed 2024-03-15 | |
| 2022-09-30 | -$114.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$549.12K derived: sum of 2 quarters · filed 2023-11-13 | $679.27K 10-Q · filed 2023-11-13 | $1.96M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$435.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $793.32K 10-Q · filed 2023-08-21 | $2.07M derived: sum of 3 quarters · filed 2023-08-21 | $2.76M derived: sum of 4 quarters · filed 2023-08-21 | |
| 2022-03-31 | $1.23M 10-Q · filed 2023-05-15 | $2.51M derived: sum of 2 quarters · filed 2023-05-15 | $3.19M derived: sum of 3 quarters · filed 2023-05-15 | $3.39M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.97M derived: sum of 2 quarters · filed 2023-03-31 | $2.16M derived: sum of 3 quarters · filed 2023-03-31 | $1.13M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $684.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $877.68K derived: sum of 2 quarters · filed 2022-11-10 | -$154.41K 10-Q · filed 2022-11-10 | -$483.89K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $193.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$838.75K 10-Q · filed 2022-08-12 | -$1.17M derived: sum of 3 quarters · filed 2022-08-12 | -$1.86M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | -$1.03M 10-Q · filed 2022-05-13 | -$1.36M derived: sum of 2 quarters · filed 2022-05-13 | -$2.05M derived: sum of 3 quarters · filed 2022-05-13 | -$2.57M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | -$329.48K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$1.02M derived: sum of 2 quarters · filed 2022-03-29 | -$1.54M derived: sum of 3 quarters · filed 2022-03-29 | -$1.16M 10-K · filed 2022-03-29 | |
| 2020-09-30 | -$691.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.21M derived: sum of 2 quarters · filed 2021-11-12 | -$827.68K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$515.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$136.03K 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | $379.54K 10-Q · filed 2021-05-18 | ||||
| 2019-12-31 | $1.97M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |